Currently, a new CD40L inhibitor, dapirolizumab pegol, is under phase III multicountry clinical trial (NCT04976322 [202]) to evaluate its TEAEs and severe lupus flares in long‐term treatment with dapirolizumab pegol. The gene discussed is CD40LG; the disease is systemic lupus erythematosus.